Release Date: 2024-05-28
Pathological Staging, Grading, and Classifi Cation of Bladder Cancer
Ferhat Keser (Author), Gozde Kir (Author)
Release Date: 2024-05-28
The tumor, node, metastasis classification is used in the staging of bladder cancer. Although it is not yet included in current urology guidelines, the prognostic significance of the T1 substaging has been suggested in many studies. The grading of bladder cancer uses the World Health Organization’s 1973 and 2004/2022 classifications, new classifications formed by their [...]
Media Type
PDF
Buy from
Price may vary by retailers
| Work Type | Book Chapter |
|---|---|
| Published in | Current Management of Non-Muscle Invasive Bladder Cancer |
| First Page | 29 |
| Last Page | 52 |
| DOI | https://doi.org/10.69860/nobel.9786053359197.3 |
| ISBN | 978-605-335-919-7 (PDF) |
| Language | ENG |
| Page Count | 24 |
| Copyright Holder | Nobel Tıp Kitabevleri |
| License | https://nobelpub.com/publish-with-us/copyright-and-licensing |
Ferhat Keser (Author)
MD, Sancaktepe Sehit Prof. Dr. Ilhan Varank Training and Research Hospital
https://orcid.org/0000-0002-2803-6481
3Ferhat Keser completed his undergraduate education at Hacettepe University Faculty of Medicine between 2007 and 2013. He started his professional career in September 2013 as a general practitioner at Sultanbeyli State Hospital Emergency Department and served in this position until June 2015. In July 2016, he started working as a resident in the Department of Urology at Istanbul Medeniyet University and received the title of Urology Specialist in September 2022. He worked as a Urology Specialist at Yüksekova State Hospital from October 2022 to December 2023. In April 2024, he was appointed as a Urology Specialist to Sancaktepe Martyr Prof. Dr. İlhan Varank Training and Research Hospital, where he currently serves. In June 2023, he received the title of Fellow of the European Board of Urology. He has twenty-two articles, sixty-two congress presentations, and four congress presentation awards, three of which are for best presentation, in the field of urology.
Gozde Kir (Author)
Istanbul Medeniyet University
https://orcid.org/0000-0003-1933-9824
3Gozde Kir is currently the Professor of Pathology at Istanbul Medeniyet University School of Medicine. She was the director of the Pathology Department of the Umraniye Education and Research Hospital (Istanbul) between 2005 and 2015. Gozde Kir has her expertise on Gynecological pathology and Uropathology. Her areas of particular interest include prediction of prostate cancer prognosis, prediction of progression following radical prostatectomy, neoplastic diseases involving the female genital tract and gynecological cytology. She has published 90 peer-reviewed articles.
1. EAU Guidelines Office, Arnhem, The Netherlands. https://uroweb.org/guidelines.
2. Younes M, Sussman J, True LD. The usefulness of the level of the muscularis mucosae in the staging of invasive transitional cell carcinoma of the urinary bladder. Cancer. 1990 Aug 1;66(3):543-8.
3. Hermann GG, Horn T, Steven K. The influence of the level of lamina propria invasion and the prevalence of p53 nuclear accumulation on survival in stage T1 transitional cell bladder cancer. J Urol. 1998 Jan;159(1):91-4.
4. Angulo JC, Lopez JI, Grignon DJ, Sanchez-Chapado M. Muscularis mucosa differentiates two populations with different prognosis in stage T1 bladder cancer. Urology. 1995 Jan;45(1):47-53.
5. Platz CE, Cohen MB, Jones MP, Olson DB, Lynch CF. Is microstaging of early invasive cancer of the urinary bladder possible or useful? Mod Pathol. 1996 Nov;9(11):1035-9.
6. Lopez-Beltran A, Algaba F, Berney DM, Boccon-Gibod L, Camparo P, Griffiths D, Mikuz G, Montironi R, Varma M, Egevad L. Handling and reporting of transurethral resection specimens of the bladder in Europe: a web-based survey by the European Network of Uropathology (ENUP). Histopathology. 2011 Mar;58(4):579- 85.
7. Cheng L, Montironi R, Davidson DD, Lopez-Beltran A. Staging and reporting of urothelial carcinoma of the urinary bladder. Mod Pathol. 2009 Jun;22 Suppl 2:S70- 95.
8. Cheng L, Neumann RM, Weaver AL, Spotts BE, Bostwick DG. Predicting cancer progression in patients with stage T1 bladder carcinoma. J Clin Oncol. 1999 Oct;17(10):3182-7.
9. Lopez-Beltran A, Cheng L. Stage pT1 bladder carcinoma: diagnostic criteria, pitfalls and prognostic significance. Pathology. 2003 Dec;35(6):484-91.
10. Jordan B, Meeks JJ. T1 bladder cancer: current considerations for diagnosis and management. Nat Rev Urol. 2019 Jan;16(1):23-34.
11. Humphrey PA, Moch H, Cubilla AL, Ulbright TM, Reuter VE. The 2016 WHO Classification of Tumors of the Urinary System and Male Genital Organs-Part B: Prostate and Bladder Tumors. Eur Urol. 2016 Jul;70(1):106-119.
12. Varma M, Srigley JR, Brimo F, Compérat E, Delahunt B, Koch M, Lopez-Beltran A, Reuter V, Samaratunga H, Shanks JH, Tsuzuki T, van der Kwast T, Webster F, Grignon D. Dataset for the reporting of urinary tract carcinoma-biopsy and transurethral resection specimen: recommendations from the International Collaboration on Cancer Reporting (ICCR). Mod Pathol. 2020 Apr;33(4):700-712.
13. Soukup V, Čapoun O, Cohen D, Hernández V, Babjuk M, Burger M, Compérat E, Gontero P, Lam T, MacLennan S, Mostafid AH, Palou J, van Rhijn BWG, Rouprêt M, Shariat SF, Sylvester R, Yuan Y, Zigeuner R. Prognostic Performance and Reproducibility of the 1973 and 2004/2016 World Health Organization Grading Classification Systems in Non-muscle-invasive Bladder Cancer: A European Association of Urology Non-muscle Invasive Bladder Cancer Guidelines Panel Systematic Review. Eur Urol. 2017 Nov;72(5):801-813.
14. Bol MG, Baak JP, Buhr-Wildhagen S, Kruse AJ, Kjellevold KH, Janssen EA, Mestad O, Øgreid P. Reproducibility and prognostic variability of grade and lamina propria invasion in stages Ta, T1 urothelial carcinoma of the bladder. J Urol. 2003 Apr;169(4):1291-4.
15. van Rhijn BWG, Hentschel AE, Bründl J, Compérat EM, Hernández V, Čapoun O, Bruins HM, Cohen D, Rouprêt M, Shariat SF, Mostafid AH, Zigeuner R, Dominguez-Escrig JL, Burger M, Soukup V, Gontero P, Palou J, van der Kwast TH, Babjuk M, Sylvester RJ; Multi-center EAU Non-Muscle-Invasive Bladder Cancer Guidelines Panel Study Consortium on the WHO1973 WHO 2004 2016 Classification Systems for Grade. Prognostic Value of the WHO1973 and WHO2004/2016 Classification Systems for Grade in Primary Ta/T1 Non-muscle-invasive Bladder Cancer: A Multicenter European Association of Urology Non-muscle-invasive Bladder Cancer Guidelines Panel Study. Eur Urol Oncol. 2021 Apr;4(2):182-191.
16. Hentschel AE, van Rhijn BWG, Bründl J, Compérat EM, Plass K, Rodríguez O, Henríquez JDS, Hernández V, de la Peña E, Alemany I, Turturica D, Pisano F, Soria F, Čapoun O, Bauerová L, Pešl M, Bruins HM, Runneboom W, Herdegen S, Breyer J, Brisuda A, Scavarda-Lamberti A, Calatrava A, Rubio-Briones J, SelesM, Mannweiler S, Bosschieter J, Kusuma VRM, Ashabere D, Huebner N, Cotte J, Mertens LS, Cohen D, Lunelli L, Cussenot O, Sheikh SE, Volanis D, Coté JF, Rouprêt M, Haitel A, Shariat SF, Mostafid AH, Nieuwenhuijzen JA, Zigeuner R, Dominguez-Escrig JL, Hacek J, Zlotta AR, Burger M, Evert M, Hulsbergen-van de Kaa CA, van der Heijden AG, Kiemeney LALM, Soukup V, Molinaro L, Gontero P, Llorente C, Algaba F, Palou J, N’Dow J, Babjuk M, van der Kwast TH, Sylvester RJ. Papillary urothelial neoplasm of low malignant potential (PUN-LMP): Still a meaningful histo-pathological grade category for Ta, noninvasive bladder tumors in 2019? Urol Oncol. 2020 May;38(5):440-448.
17. Raspollini MR, Comperat EM, Lopez-Beltran A, Montironi R, Cimadamore A, Tsuzuki T, Netto GJ. News in the classification of WHO 2022 bladder tumors. Pathologica. 2022 Feb;115(1):32-40.
18. Akhtar M, Al-Bozom IA, Ben Gashir M, Taha NM, Rashid S, Al-Nabet ADMH. Urothelial Carcinoma In Situ (CIS): New Insights. Adv Anat Pathol. 2019 Sep;26(5):313-319.
19. Nese N, Gupta R, Bui MH, Amin MB. Carcinoma in situ of the urinary bladder: review of clinicopathologic characteristics with an emphasis on aspects related to molecular diagnostic techniques and prognosis. J Natl Compr Canc Netw. 2009 Jan;7(1):48-57.
20. Williamson SR, Montironi R, Lopez-Beltran A, MacLennan GT, Davidson DD, Cheng L. Diagnosis, evaluation and treatment of carcinoma in situ of the urinary bladder: the state of the art. Crit Rev Oncol Hematol. 2010 Nov;76(2):112-26.
21. Casey RG, Catto JW, Cheng L, Cookson MS, Herr H, Shariat S, Witjes JA, Black PC. Diagnosis and management of urothelial carcinoma in situ of the lower urinary tract: a systematic review. Eur Urol. 2015 May;67(5):876-88.
22. Cheng L, Davidson DD, Maclennan GT, Williamson SR, Zhang S, Koch MO, Montironi R, Lopez-Beltran A. The origins of urothelial carcinoma. Expert Rev Anticancer Ther. 2010 Jun;10(6):865-80.
23. Takenaka A, Yamada Y, Miyake H, Hara I, Fujisawa M. Clinical outcomes of bacillus Calmette-Guérin instillation therapy for carcinoma in situ of urinary bladder. Int J Urol. 2008 Apr;15(4):309-13.
24. Humphrey PA. Urothelial carcinoma in situ of the bladder. J Urol. 2012 Mar;187(3):1057-8.
25. Cheng L, Cheville JC, Neumann RM, Bostwick DG. Flat intraepithelial lesions of the urinary bladder. Cancer. 2000 Feb 1;88(3):625-31.
26. Amin MB, McKenney JK. An approach to the diagnosis of flat intraepithelial lesions of the urinary bladder using the World Health Organization/ International Society of Urological Pathology consensus classification system. Adv Anat Pathol. 2002 Jul;9(4):222-32.
27. Hodges KB, Lopez-Beltran A, Emerson RE, Montironi R, Cheng L. Clinical utility of immunohistochemistry in the diagnoses of urinary bladder neoplasia. Appl Immunohistochem Mol Morphol. 2010 Oct;18(5):401-10.
28. Aron M, Luthringer DJ, McKenney JK, Hansel DE, Westfall DE, Parakh R, Mohanty SK, Balzer B, Amin MB. Utility of a triple antibody cocktail intraurothelial neoplasm-3 (IUN-3-CK20/CD44s/p53) and α-methylacyl-CoA racemase (AMACR) in the distinction of urothelial carcinoma in situ (CIS) and reactive urothelial atypia. Am J Surg Pathol. 2013 Dec;37(12):1815-23.
29. Amin MB, Trpkov K, Lopez-Beltran A, Grignon D; Members of the ISUP Immunohistochemistry in Diagnostic Urologic Pathology Group. Best practices recommendations in the application of immunohistochemistry in the bladder lesions: report from the International Society of Urologic Pathology consensus conference. Am J Surg Pathol. 2014 Aug;38(8):e20-34.
30. Sugino T, Gorham H, Yoshida K, Bolodeoku J, Nargund V, Cranston D, Goodison S, Tarin D. Progressive loss of CD44 gene expression in invasive bladder cancer. Am J Pathol. 1996 Sep;149(3):873-82.
31. Desai S, Lim SD, Jimenez RE, Chun T, Keane TE, McKenney JK, Zavala-Pompa A, Cohen C, Young RH, Amin MB. Relationship of cytokeratin 20 and CD44 protein expression with WHO/ISUP grade in pTa and pT1 papillary urothelial neoplasia. Mod Pathol. 2000 Dec;13(12):1315-23.
32. McKenney JK, Desai S, Cohen C, Amin MB. Discriminatory immunohistochemical staining of urothelial carcinoma in situ and non-neoplastic urothelium: an analysis of cytokeratin 20, p53, and CD44 antigens. Am J Surg Pathol. 2001 Aug;25(8):1074-8.
33. Edgecombe A, Nguyen BN, Djordjevic B, Belanger EC, Mai KT. Utility of cytokeratin 5/6, cytokeratin 20, and p16 in the diagnosis of reactive urothelial atypia and noninvasive component of urothelial neoplasia. Appl Immunohistochem Mol Morphol. 2012 May;20(3):264-71.
34. Mai KT, Busca A, Belanger EC. Flat Intraurothelial Neoplasia Exhibiting Diffuse Immunoreactivity for CD44 and Cytokeratin 5 (Urothelial Stem Cell/Basal Cell Markers): A Variant of Intraurothelial Neoplasia Commonly Associated With Muscle-invasive Urothelial Carcinoma. Appl Immunohistochem Mol Morphol. 2017 Aug;25(7):505-512.
35. Gakis G, Todenhöfer T, Braun M, Fend F, Stenzl A, Perner S. Immunohistochemical assessment of lymphatic and blood vessel invasion in T1 urothelial carcinoma of the bladder. Scand J Urol. 2015;49(5):382-7.
36. Mari A, Kimura S, Foerster B, Abufaraj M, D’Andrea D, Hassler M, Minervini A, Rouprêt M, Babjuk M, Shariat SF. A systematic review and meta-analysis of the impact of lymphovascular invasion in bladder cancer transurethral resection specimens. BJU Int. 2019 Jan;123(1):11-21.
37. Kim HS, Kim M, Jeong CW, Kwak C, Kim HH, Ku JH. Presence of lymphovascular invasion in urothelial bladder cancer specimens after transurethral resections correlates with risk of upstaging and survival: a systematic review and meta-analysis. Urol Oncol. 2014 Nov;32(8):1191-9.
38. Wasco MJ, Daignault S, Zhang Y, Kunju LP, Kinnaman M, Braun T, Lee CT, Shah RB. Urothelial carcinoma with divergent histologic differentiation (mixed histologic features) predicts the presence of locally advanced bladder cancer when detected at transurethral resection. Urology. 2007 Jul;70(1):69-74.
39. Cai T, Tiscione D, Verze P, Pomara G, Racioppi M, Nesi G, Barbareschi M, Brausi M, Gacci M, Luciani LG, Liguori G, Gontero P, Campodonico F, Simonato A, Boddi V, Di Stasi SM, Colombo R, Serretta V, Carmignani G, Malossini G, Altieri V, Carini M, Terrone C, Bassi P, Montorsi F, Ficarra V, Selli C, Mirone V, Bartoletti R. Concordance and clinical significance of uncommon variants of bladder urothelial carcinoma in transurethral resection and radical cystectomy specimens. Urology. 2014 Nov;84(5):1141-6.
40. Compérat E, Oszwald A, Wasinger G, Hansel DE, Montironi R, van der Kwast T, Witjes JA, Amin MB. Updated pathology reporting standards for bladder cancer: biopsies, transurethral resections and radical cystectomies. World J Urol. 2022 Apr;40(4):915-927.
41. Compérat E, Amin MB, Epstein JI, Hansel DE, Paner G, Al-Ahmadie H, True L, Bayder D, Bivalacqua T, Brimo F, Cheng L, Cheville J, Dalbagni G, Falzarano S, Gordetsky J, Guo C, Gupta S, Hes O, Iyer G, Kaushal S, Kunju L, Magi-Galluzzi C, Matoso A, McKenney J, Netto GJ, Osunkoya AO, Pan CC, Pivovarcikova K, Raspollini MR, Reis H, Rosenberg J, Roupret M, Shah RB, Shariat SF, Trpkov K, Weyerer V, Zhou M, Reuter V. The Genitourinary Pathology Society Update on Classification of Variant Histologies, T1 Substaging, Molecular Taxonomy, and Immunotherapy and PD-L1 Testing Implications of Urothelial Cancers. Adv Anat Pathol. 2021 Jul 1;28(4):196-208.
42. Gandhi J, Chen JF, Al-Ahmadie H. Urothelial Carcinoma: Divergent Differentiation and Morphologic Subtypes. Surg Pathol Clin. 2022 Dec;15(4):641-659.
43. Ehdaie B, Maschino A, Shariat SF, Rioja J, Hamilton RJ, Lowrance WT, Poon SA, Al-Ahmadie HA, Herr HW. Comparative outcomes of pure squamous cell carcinoma and urothelial carcinoma with squamous differentiation in patients treated with radical cystectomy. J Urol. 2012 Jan;187(1):74-9.
44. Xylinas E, Rink M, Robinson BD, Lotan Y, Babjuk M, Brisuda A, Green DA, Kluth LA, Pycha A, Fradet Y, Faison T, Lee RK, Karakiewicz PI, Zerbib M, Scherr DS, Shariat SF. Impact of histological variants on oncological outcomes of patients with urothelial carcinoma of the bladder treated with radical cystectomy. Eur J Cancer. 2013 May;49(8):1889-97.
45. Park S, Reuter VE, Hansel DE. Non-urothelial carcinomas of the bladder. Histopathology. 2019 Jan;74(1):97-111.
46. Rogers CG, Palapattu GS, Shariat SF, Karakiewicz PI, Bastian PJ, Lotan Y, Gupta A, Vazina A, Gilad A, Sagalowsky AI, Lerner SP, Schoenberg MP. Clinical outcomes following radical cystectomy for primary nontransitional cell carcinoma of the bladder compared to transitional cell carcinoma of the bladder. J Urol. 2006 Jun;175(6):2048-53; discussion 2053.
47. Kim SP, Frank I, Cheville JC, Thompson RH, Weight CJ, Thapa P, Boorjian SA. The impact of squamous and glandular differentiation on survival after radical cystectomy for urothelial carcinoma. J Urol. 2012 Aug;188(2):405-9.
48. Almassi N, Whiting K, Toubaji A, Lenis AT, Jordan EJ, Won H, Regazzi AM, Chen YB, Gopalan A, Sirintrapun SJ, Fine SW, Tickoo SK, Ostrovnaya I, Pietzak EJ, Cha EK, Goh AC, Donahue TF, Herr HW, Donat SM, Dalbagni G, Bochner BH, Teo MY, Funt SA, Rosenberg JE, Reuter VE, Bajorin DF, Solit DB, Al-Ahmadie H, Iyer G. Clinical and Genomic Characterization of Bladder Carcinomas With Glandular Phenotype. JCO Precis Oncol. 2022 Jun;6:e2100392.
49. Lughezzani G, Sun M, Jeldres C, Alasker A, Budäus L, Shariat SF, Latour M, Widmer H, Duclos A, Jolivet-Tremblay M, Montorsi F, Perrotte P, Karakiewicz PI. Adenocarcinoma versus urothelial carcinoma of the urinary bladder: comparison between pathologic stage at radical cystectomy and cancer-specific mortality. Urology. 2010 Feb;75(2):376-81.
50. Oliva E, Amin MB, Jimenez R, Young RH. Clear cell carcinoma of the urinary bladder: a report and comparison of four tumors of mullerian origin and nine of probable urothelial origin with discussion of histogenesis and diagnostic problems. Am J Surg Pathol. 2002 Feb;26(2):190-7.
51. Sung MT, Zhang S, MacLennan GT, Lopez-Beltran A, Montironi R, Wang M, Tan PH, Cheng L. Histogenesis of clear cell adenocarcinoma in the urinary tract: evidence of urothelial origin. Clin Cancer Res. 2008 Apr 1;14(7):1947-55.
52. Kösem M, Sengül E. Clear cell adenocarcinoma of the urinary bladder. Scand J Urol Nephrol. 2005;39(1):89-92.
53. Chang MT, Penson A, Desai NB, Socci ND, Shen R, Seshan VE, Kundra R, Abeshouse A, Viale A, Cha EK, Hao X, Reuter VE, Rudin CM, Bochner BH, Rosenberg JE, Bajorin DF, Schultz N, Berger MF, Iyer G, Solit DB, Al-Ahmadie HA, Taylor BS. Small-Cell Carcinomas of the Bladder and Lung Are Characterized by a Convergent but Distinct Pathogenesis. Clin Cancer Res. 2018 Apr 15;24(8):1965-1973.
54. Veskimäe E, Espinos EL, Bruins HM, Yuan Y, Sylvester R, Kamat AM, Shariat SF, Witjes JA, Compérat EM. What Is the Prognostic and Clinical Importance of Urothelial and Nonurothelial Histological Variants of Bladder Cancer in Predicting Oncological Outcomes in Patients with Muscle-invasive and Metastatic Bladder Cancer? A European Association of Urology Muscle Invasive and Metastatic Bladder Cancer Guidelines Panel Systematic Review. Eur Urol Oncol. 2019 Nov;2(6):625-642.
55. Lynch SP, Shen Y, Kamat A, Grossman HB, Shah JB, Millikan RE, Dinney CP, Siefker-Radtke A. Neoadjuvant chemotherapy in small cell urothelial cancer improves pathologic downstaging and long-term outcomes: results from a retrospective study at the MD Anderson Cancer Center. Eur Urol. 2013 Aug;64(2):307-13.
56. Cheng HL, Chou LP, Tsai HW, Lee CT, Wang YW, Chung-Liang H, Ou JH, Tsai YS, Chow NH. Urothelial carcinoma with trophoblastic differentiation: Reappraisal of the clinical implication and immunohistochemically features. Urol Oncol. 2021 Oct;39(10):732.e17-732.e23.
57. Amin MB. Histological variants of urothelial carcinoma: diagnostic, therapeutic and prognostic implications. Mod Pathol. 2009 Jun;22 Suppl 2:S96-S118.
58. Przybycin CG, McKenney JK, Nguyen JK, Shah RB, Umar SA, Harik L, Shih IM, Cox RM. Urothelial Carcinomas With Trophoblastic Differentiation, Including Choriocarcinoma: Clinicopathologic Series of 16 Cases. Am J Surg Pathol. 2020 Oct;44(10):1322-1330.
59. Sangoi AR, Beck AH, Amin MB, Cheng L, Epstein JI, Hansel DE, Iczkowski KA, Lopez-Beltran A, Oliva E, Paner GP, Reuter VE, Ro JY, Shah RB, Shen SS, Tamboli P, McKenney JK. Interobserver reproducibility in the diagnosis of invasive micropapillary carcinoma of the urinary tract among urologic pathologists. Am J Surg Pathol. 2010 Sep;34(9):1367-76.
60. Fairey AS, Daneshmand S, Wang L, Schuckman A, Lieskovsky G, Djaladat H, Cai J, Miranda G, Skinner EC. Impact of micropapillary urothelial carcinoma variant histology on survival after radical cystectomy. Urol Oncol. 2014 Feb;32(2):110-6.
61. Mitra AP, Fairey AS, Skinner EC, Boorjian SA, Frank I, Schoenberg MP, Bivalacqua TJ, Hyndman ME, Reese AC, Steinberg GD, Large MC, Hulsbergen-van de Kaa CA, Bruins HM, Daneshmand S. Implications of micropapillary urothelial carcinoma variant on prognosis following radical cystectomy: A multi-institutional investigation. Urol Oncol. 2019 Jan;37(1):48-56.
62. Wang JK, Boorjian SA, Cheville JC, Kim SP, Tarrell RF, Thapa P, Frank I. Outcomes following radical cystectomy for micropapillary bladder cancer versus pure urothelial carcinoma: a matched cohort analysis. World J Urol. 2012 Dec;30(6):801-6.
63. Nigwekar P, Tamboli P, Amin MB, Osunkoya AO, Ben-Dor D, Amin MB. Plasmacytoid urothelial carcinoma: detailed analysis of morphology with clinicopathologic correlation in 17 cases. Am J Surg Pathol. 2009 Mar;33(3):417-24.
64. Teo MY, Al-Ahmadie H, Seier K, Tully C, Regazzi AM, Pietzak E, Solit DB, Tickoo S, Reuter V, Cha EK, Herr H, Donahue T, Donat SM, Dalbagni G, Bochner BH, Funt S, Iyer GV, Bajorin DF, Ostrovnaya I, Rosenberg JE. Natural history, response to systemic therapy, and genomic landscape of plasmacytoid urothelial carcinoma. Br J Cancer. 2021 Mar;124(7):1214-1221.
65. Keck B, Wach S, Stoehr R, Kunath F, Bertz S, Lehmann J, Stöckle M, Taubert H, Wullich B, Hartmann A. Plasmacytoid variant of bladder cancer defines patients with poor prognosis if treated with cystectomy and adjuvant cisplatin-based chemotherapy. BMC Cancer. 2013 Feb 8;13:71.
66. Drew PA, Furman J, Civantos F, Murphy WM. The nested variant of transitional cell carcinoma: an aggressive neoplasm with innocuous histology. Mod Pathol. 1996 Oct;9(10):989-94.
67. Compérat E, McKenney JK, Hartmann A, Hes O, Bertz S, Varinot J, Brimo F. Large nested variant of urothelial carcinoma: a clinicopathological study of 36 cases. Histopathology. 2017 Nov;71(5):703-710.
68. Cox R, Epstein JI. Large nested variant of urothelial carcinoma: 23 cases mimicking von Brunn nests and inverted growth pattern of noninvasive papillary urothelial carcinoma. Am J Surg Pathol. 2011 Sep;35(9):1337-42.
69. Young RH, Zukerberg LR. Microcystic transitional cell carcinomas of the urinary bladder. A report of four cases. Am J Clin Pathol. 1991 Nov;96(5):635-9.
70. Zukerberg LR, Harris NL, Young RH. Carcinomas of the urinary bladder simulating malignant lymphoma. A report of five cases. Am J Surg Pathol. 1991 Jun;15(6):569-76.
71. Manocha U, Kardos J, Selitsky S, Zhou M, Johnson SM, Breslauer C, Epstein JI, Kim WY, Wobker SE. RNA Expression Profiling of Lymphoepithelioma-Like Carcinoma of the Bladder Reveals a Basal-Like Molecular Subtype. Am J Pathol. 2020 Jan;190(1):134-144.
72. Amin MB, Ro JY, Lee KM, Ordóñez NG, Dinney CP, Gulley ML, Ayala AG. Lymphoepithelioma-like carcinoma of the urinary bladder. Am J Surg Pathol. 1994 May;18(5):466-73.
73. Williamson SR, Zhang S, Lopez-Beltran A, Shah RB, Montironi R, Tan PH, Wang M, Baldridge LA, MacLennan GT, Cheng L. Lymphoepithelioma-like carcinoma of the urinary bladder: clinicopathologic, immunohistochemical, and molecular features. Am J Surg Pathol. 2011 Apr;35(4):474-83.
74. Lopez-Beltran A, Amin MB, Oliveira PS, Montironi R, Algaba F, McKenney JK, de Torres I, Mazerolles C, Wang M, Cheng L. Urothelial carcinoma of the bladder, lipid cell variant: clinicopathologic findings and LOH analysis. Am J Surg Pathol. 2010 Mar;34(3):371-6.
75. Borzacchiello G, Ambrosio V, Leonardi L, Fruci R, Galati P, Roperto F. Rare tumors in domestic animals: a lipid cell variant of urothelial carcinoma of the urinary bladder in a cow and a case of vesical carcinosarcoma in a dog. Vet Res Commun. 2004 Aug;28 Suppl 1:273-4.
76. Lopez-Beltran A, Blanca A, Montironi R, Cheng L, Regueiro JC. Pleomorphic giant cell carcinoma of the urinary bladder. Hum Pathol. 2009 Oct;40(10):1461-6.
77. Samaratunga H, Delahunt B, Egevad L, Adamson M, Hussey D, Malone G, Hoyle K, Nathan T, Kerle D, Ferguson P, Nacey JN. Pleomorphic giant cell carcinoma of the urinary bladder: an extreme form of tumor de-differentiation. Histopathology. 2016 Mar;68(4):533-40.
78. Sanfrancesco J, McKenney JK, Leivo MZ, Gupta S, Elson P, Hansel DE. Sarcomatoid Urothelial Carcinoma of the Bladder: Analysis of 28 Cases With Emphasis on Clinicopathologic Features and Markers of Epithelial-to-Mesenchymal Transition. Arch Pathol Lab Med. 2016 Jun;140(6):543-51.
79. Lopez-Beltran A, Pacelli A, Rothenberg HJ, Wollan PC, Zincke H, Blute ML, Bostwick DG. Carcinosarcoma and sarcomatoid carcinoma of the bladder: clinicopathological study of 41 cases. J Urol. 1998 May;159(5):1497-503.
| onix_3.0::thoth | Thoth ONIX 3.0 |
|---|---|
| onix_3.0::project_muse | Project MUSE ONIX 3.0 |
| onix_3.0::oapen | OAPEN ONIX 3.0 |
| onix_3.0::jstor | JSTOR ONIX 3.0 |
| onix_3.0::google_books | Google Books ONIX 3.0 |
| onix_3.0::overdrive | OverDrive ONIX 3.0 |
| onix_2.1::ebsco_host | EBSCO Host ONIX 2.1 |
| csv::thoth | Thoth CSV |
| json::thoth | Thoth JSON |
| kbart::oclc | OCLC KBART |
| bibtex::thoth | Thoth BibTeX |
| doideposit::crossref | CrossRef DOI deposit |
| onix_2.1::proquest_ebrary | ProQuest Ebrary ONIX 2.1 |
| marc21record::thoth | Thoth MARC 21 Record |
| marc21markup::thoth | Thoth MARC 21 Markup |
| marc21xml::thoth | Thoth MARC 21 XML |
